Patents by Inventor Michal Besser

Michal Besser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR EXPANDING T CELL POPULATIONS
    Publication number: 20170296584
    Abstract: The present invention provides methods for expanding populations of T cell. The present invention further provides pharmaceutical compositions comprising the expanded T cells, including, ?? T cells, and use thereof for treating infectious, autoimmune or malignant diseases.
    Type: Application
    Filed: September 24, 2015
    Publication date: October 19, 2017
    Applicant: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Ilan BANK, Michal BESSER, Victoria MARCU
  • Method of predicting responsiveness to autologous adoptive cell transfer therapy
    Patent number: 8541185
    Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28?CD152? signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28?CD152? signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: September 24, 2013
    Assignees: Technion Research & Development Foundation Limited, Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Kfir Oved, Eran Eden, Martin Akerman, Roy Noy, Michal Besser, Yoram Reiter
  • T CELL SUBPOPULATIONS CAPABLE OF TREATING CANCER
    Publication number: 20100310534
    Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28?CD152? signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28?CD152? signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.
    Type: Application
    Filed: September 15, 2008
    Publication date: December 9, 2010
    Inventors: Kfir Oved, Eran Eden, Martin Akerman, Roy Noy, Michal Besser, Yoram Reiter